Pharma Stocks Plunge on Trump Tariff Threat

New Delhi:  Shares of Pharmaceutical companies on Friday tumbled up to 10 per cent amid reports that the Trump Administration will soon announce tariffs on pharma imports and emphasised that the measures will be “unprecedented”.

According to reports, President Trump has said that tariffs on pharmaceuticals and semiconductors will be announced shortly, emphasising that the measures on pharmaceutical imports will be unprecedented.

The US has announced 26 per cent reciprocal tariffs on India saying New Delhi imposes high import duties on American goods.

Reacting to the reports the stock of Aurobindo Pharma plunged 11 per cent to Rs 1,049.85 apiece on the, Laurus Labs tumbled 9.5 per cent to Rs 561.55, Ipca labs decreased 9.3 per cent to Rs 1,357.80, Lupin dipped 8.41 per cent to Rs 1,918.20, Biocon 7.03 per cent to Rs 321.25, and Cipla declined 7 per cent to Rs 1,390.35.

In addition, Marksans Pharma’s shares depreciated 6.7 per cent to Rs 217.40 per piece, Dr Reddys Laboratories declined 6.5 per cent to Rs 1,076.40 — also its 52-week low — Shilpa Medicare fell 6.4 per cent to Rs 633, and Sun Pharmaceutical Industries slipped 6.33 per cent to Rs 1,658.

Also, the scrip of Gland Pharma dipped 6 per cent to Rs 1,468.25 per share, Ajanta Pharma fell 5.4 per cent to Rs 2,480.05, Wockhardt depreciated by 5 per cent to hit a lower circuit band of Rs 1,347.55 on the exchange.

In Morning trade on Friday, the BSE healthcare index declined 1,347.88 points or 3.22 per cent to 40,522.91, while the 30-share BSE Sensex slumped 680.18 points or 0.89 per cent to 75,615.18.

Earlier, the Trump administration had exempted pharmaceuticals and semiconductors from the reciprocal tariff policy. Accordingly, shares of Pharmaceutical companies on Thursday had settled with gains of as much as 7 per cent.

Related Posts

  • Pharma
  • April 28, 2025
  • 16 views
Gujrat leads pharma sector with record 183 new plants

Ahmedabad:  Gujarat has further cemented its position as India’s pharmaceutical powerhouse with the state’s Food and Drug Control Administration (FDCA) approving 183 new allopathic drug manufacturing facilities in FY 2024-25,…

  • Pharma
  • April 28, 2025
  • 57 views
Doctor not liable for prescribing costly drug: HC

Cuttack:  Orissa high court has ruled that a doctor should not be held criminally liable for prescribing a particular drug of any pharmaceutical company for treatment of a disease like…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Gujrat leads pharma sector with record 183 new plants

Gujrat leads pharma sector with record 183 new plants

Doctor not liable for prescribing costly drug: HC

Doctor not liable for prescribing costly drug: HC

878 Tramadol capsules being smuggled in Scorpio seized, three arrested

878 Tramadol capsules being smuggled in Scorpio seized, three arrested

Doctor not criminally liable for prescribing costly drug: Orissa High Court

Doctor not criminally liable for prescribing costly drug: Orissa High Court

Merger of Suven Pharma, Cohance Lifesciences to take effect from May 1

Merger of Suven Pharma, Cohance Lifesciences to take effect from May 1

Dr Lal PathLabs Q4 profit rises 81% on volume growth, geographic expansion

Dr Lal PathLabs Q4 profit rises 81% on volume growth, geographic expansion